Veritas Aortic Solutions was spun out of inQB8 Medical Technologies in late 2025 and is developing the Veritas Transcatheter Valved Aortic Root Conduit (TVARC), a single permanent implant intended to treat root and ascending aortic diseases. The TVARC combines a bioprosthetic aortic valve, an ascending aortic graft, and the company's Chameleon Eye™ coronary perfusion ports, and is delivered via a custom transfemoral catheter for precise positioning and controlled deployment. The company reports progression through prototyping, bench testing, and successful chronic animal studies. Veritas raised $12M in Seed financing to advance the TVARC through First-in-Human clinical use. Leadership changes tied to the financing include the addition of experienced MedTech executives and CSIPCo representation on the board. The company is headquartered in Costa Mesa, California.

Total raised

$12M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2026